Skip to main content
AROA BIOSURGERY LIMITED logo

AROA BIOSURGERY LIMITED — Investor Relations & Filings

Ticker · ARX ISIN · NZARXE0001S1 ASX Manufacturing
Open in API
Filings indexed 331 across all filing types
Latest filing 2026-05-18 Report Publication Anno…
Country AU Australia
Listing ASX ARX

About AROA BIOSURGERY LIMITED

https://aroa.com/

Aroa Biosurgery Limited specializes in the development and commercialization of regenerative medical devices for wound healing and soft tissue reconstruction. The company’s core technology is the AROA ECM platform, a proprietary extracellular matrix derived from ovine forestomach tissue. This scaffold-based technology is engineered to facilitate host cell infiltration and promote new blood vessel formation, supporting the body's natural healing process. The product portfolio includes Endoform for chronic and acute wound management, Myriad for complex surgical applications, and Symphony for skin substitute procedures. Additionally, the company manufactures the Ovitex and Ovitex PRS reinforced tissue matrices for hernia repair and breast reconstruction. These solutions target clinical needs in advanced wound care and surgical specialties by providing biological scaffolds that integrate into host tissue.

Recent filings

Filing Released Lang Actions
Notification of Full Year Results Webinar 1
Report Publication Announcement Classification · 85% confidence The document is a regulatory announcement (ASX) notifying investors of an upcoming webinar to discuss the Company’s Full Year 2026 Audited Financial Results and stating the release timing (pre-market on 26 May 2026). It contains no financial data itself and does not attach the report; rather it announces the timing and event. This matches a Report Publication Announcement (RPA).
2026-05-18 English
ARX FY26 Preliminary Results 2 pages 308.8KB
Earnings Release Classification · 95% confidence The document is an ASX announcement dated 30 April 2026 from Aroa Biosurgery Limited presenting preliminary unaudited financial results highlights for the fiscal year ended 31 March 2026. It includes key financial metrics such as total revenue, normalized EBITDA, cash flow, and cash balance. The document explicitly states these are preliminary and unaudited results and mentions that the fully audited FY26 results will be released later on 26 May 2026. The document is relatively short (4402 characters) and serves as an initial earnings update rather than a full financial report. This fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR), nor is it a report publication announcement (RPA) because it contains substantive financial data and not just a notice of report availability.
2026-04-29 English
Application for quotation of securities - ARX 6 pages 19.6KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement for the application for quotation of securities. It details the issuance and quotation of new securities resulting from the exercise of options or conversion of convertible securities. The document includes specifics such as the number of securities, issue dates, and whether the securities are part of an employee incentive scheme. This type of announcement is related to changes in the company's capital structure, specifically the issuance and quotation of new shares. It is not a full financial report, earnings release, or management discussion, but rather a formal notification of a capital change event. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is not merely an announcement of a report but a substantive filing about securities quotation.
2026-04-09 English
Notification of cessation of securities - ARX 5 pages 17.8KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation (expiry or lapse) of various securities such as restricted stock units, options, and performance rights for AROA BIOSURGERY LIMITED. It includes specific ASX security codes, reasons for cessation, dates, and updated issued capital figures. The document is a regulatory announcement notifying the market and ASX of securities that have ceased to exist or lapsed. It does not contain financial statements, management discussion, or detailed financial results. It is not a report but a formal notification of changes in securities status. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-04-08 English
Symphony Randomised Control Trial Complete 2 pages 293.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 30 March 2026 from Aroa Biosurgery Limited. It reports the completion of a randomised controlled trial (RCT) for their product Symphony, including preliminary findings and future publication plans. The content focuses on clinical trial results and their implications for product adoption and reimbursement. The document is relatively short (4040 characters) and serves as an announcement of trial completion and preliminary results rather than a full clinical study report or detailed financial or regulatory filing. It does not contain financial statements, management discussion, or regulatory certifications. It is not a report publication announcement since it does not mention an attached or published report but rather announces trial completion and preliminary findings. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial progress and results that do not fit into other specific categories such as financial reports, management changes, or capital updates.
2026-03-29 English
Release of Shares from Voluntary Escrow 1 page 254.
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 24 March 2026 regarding the release of shares from voluntary escrow. It references ASX Listing Rule 3.10A and details the number of shares being released from escrow, the date of release, and the background of the shares issued to a non-executive director following shareholder approval at the 2024 AGM. The document is short (1973 characters) and is an announcement about share release, not a financial report or detailed filing. It does not contain financial statements or detailed financial data. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about share escrow release and does not fit other more specific categories like Share Issue/Capital Change (SHA) because it is about release from escrow, not new issuance or capital change. Therefore, the best classification is Regulatory Filings (RNS).
2026-03-23 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.